Majority of carriers of hepatitis B virus remain asymptomatic during the initial phase of acute infection, albeit some suffer from acute symptoms which prevail for few weeks. Like hepatitis B ...

Barinthus Biotherapeutics has shared its most significant recent data from the ongoing Phase IIb HBV003 clinical trial for chronic hepatitis B. The newest data was cut off on 30 September (for lab ...

Vir Biotechnology’s ‘functional cure’ combination therapy has failed to meet the efficacy endpoints in a Phase II trial in hepatitis B. The company reported data from the 24-week point of ...

31, 2024 (GLOBE NEWSWIRE) -- The "Hepatitis B - Global Clinical Trials Review ... country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent ...

An antisense drug in development at GSK has shown further activity against hepatitis B virus (HBV) in a mid-stage trial, setting up a phase 3 assessment next year to see if it could offer a ...

In the latest results from the 457-patient B-Clear study, published in the New England Journal of Medicine, bepirovirsen at a dose of 300 mg per week over 24 weeks resulted in sustained hepatitis ...

Chronic hepatitis B infection is caused by HBV and is a major global health concern, affecting nearly 300 million people worldwide. Data from the Phase 2b B-Clear study demonstrated the potential ...

(Nasdaq: VIR) today announced it will be presenting new data from its ongoing Phase 2 SOLSTICE ... could have for chronic hepatitis delta (CHD) and chronic hepatitis B (CHB) patients at the ...

The investigational combo of Vir’s monoclonal antibody tobevibart and Alnylam-discovered siRNA elebsiran was measured in a phase 2 trial for patients with chronic hepatitis B (CHB). Participants ...